Key result
Long-term clopidogrel therapy after percutaneous coronary intervention may lack the robust clinical benefits previously attributed to it by the PCI-CURE and CREDO trials.
Authors
Loading...
Questions extended clopidogrel post-PCI; leaves open need for contemporary trials to reassess PCI-CURE and CREDO findings.
Key points are not available for this paper at this time.
Peter Eriksson (2004) studied this question. Long-term clopidogrel therapy after percutaneous coronary intervention may lack the robust clinical benefits previously attributed to it by the PCI-CURE and CREDO trials.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: